The role of CYP1A1 genotype in lung cancer risk was assessed in African Americans through a case control study. The complete CYP1A1 genotype, including the frequency of all three polymorphisms (Msp1 [CYP1A1*2], exon 7 [CYP1A1*3] and African American specific [CYP1A1*4]) was determined by PCR on 307 controls and 105 cases of lung cancer among African Americans. We have confirmed our earlier observation of a significant increased risk (odds ratio ϭ 2.8, 95% CI ϭ 1.3-6.5) for lung adenocarcinoma among people with the *4 polymorphism, although we did not observe any association of this polymorphism with overall lung cancer risk. As previously reported, we found that lung adenocarcinoma patients with the *4 RFLP smoked significantly less than patients without this polymorphism, suggesting an important role in cancer risk of low exposure levels to cigarette smoke in subjects carrying susceptibility polymorphisms. There was no association with the other two polymorphisms and lung cancer in this population. When we examined lung cancer risk as a function of composite genotype, taking into account all three polymorphisms simultaneously in each subject, our preliminary data suggested an association of one rare genotype (homozygous Msp1, heterozygous exon 7 or *2/ *2*3) with overall lung cancer risk (OR ϭ 8.4, 95% CI ϭ 1.6-43.2).
Introduction
The role of metabolic genes in individual susceptibility to the carcinogenic effects of tobacco smoke has been studied in several populations (1) (2) (3) (4) (5) but only recently in African Americans (6) (7) (8) (9) (10) (11) . The CYP1A1 gene, which plays a critical role in the metabolism of tobacco smoke derived aromatic hydrocarbons, contains three important sequence polymorphisms (12) (13) (14) , one of which is specific to people of African descent (15) . These polymorphisms have been found to be associated with increased risk of several cancers, including lung, breast, and colon in specific ethnic groups. For example, the *3 polymorphism in exon 7 has been found to be a risk factor for lung cancer in Japanese (12, 16) , but not in Caucasians (17, 18) ; the *2 RFLP is associated with lung and colon cancer in Japanese (3, 19) , with breast cancer in African Americans (20) , and possibly with lung cancer in Caucasians (21) . The African American specific *4 RFLP has been examined in relation to lung adenocarcinoma in African Americans with inconsistent results (9, 11) .
To date all studies on the relationship between CYP1A1 genotype and cancer have examined each polymorphism separately, without taking into account the possible simultaneous occurrence of two or more polymorphisms in an individual genotype. No studies published to date have examined the association of complete composite CYP1A1 genotype with cancer. We have taken the approach of considering the distribution of different alleles composed of all possible combinations of polymorphisms (for example in African Americans there are three polymorphisms and therefore eight possible alleles) to clarify the composite CYP1A1 genotype of individuals (14) . We have expanded our previous work on African American lung cancer and CYP1A1 genotype (9) by inclusion of a larger study population, and by analysis of the complete CYP1A1 genotype, including all three polymorphic loci, in a casecontrol study.
Material and methods
We analyzed DNA extracted from archived tissue blocks from 80 AfricanAmerican incident cases of lung cancer collected at NYU Medical Center between 1984 and 1992, and 25 lung cancer cases collected at Harlem Hospital during the years 1993-1995. DNA was extracted from archived tissue blocks from subjects recruited at NYU, and from fresh whole blood from subjects recruited at Harlem Hospital. The prevalence of the CYP1A1 polymorphisms in the cases was compared to that observed in peripheral blood lymphocytes of 307 African-American controls. These were healthy volunteers recruited from the community living in the eastern US (n ϭ 247), and patients admitted at Harlem Hospital for non-tobacco related diseases other than cancer (n ϭ 60). All the participants answered a brief questionnaire and signed a written informed consent. Random codes were assigned to all the samples prior to delivery to the laboratory, and all genotype analyses were conducted double blind. Four samples have been excluded because of the poor quality of the DNA obtained. Complete genotype information (all three polymorphisms) was available for 278 controls and 96 cases for which DNA was available.
RFLP analysis by PCR
DNA was amplified by PCR before digestion with Msp I. DNA was amplified in a total reaction volume of 50 µl containing 1.2 mM dNTP, 1.2 µM oligonucleotide primers, and 2.5 units TAQ polymerase (Amplitaq, PerkinElmer, Norwalk, CT). DNA samples were amplified using the following primers: 5Ј-CTGACTGGCTTCAGCAAGTT and 3Ј-TAGGAGTCTTGTCTC-ATGCCT. PCR was performed for 45 cycles with denaturing at 95°C for 1 min, annealing at 56°C for 1 min, and extension at 65°C for 2 min. PCR products were digested with excess Msp I (New England Biolabs, Beverley, MA) for 3 h, and then electrophoresed through 1.8% agarose and visualized by ethidium bromide staining. These conditions allow for simultaneous detection of both the *2 and *4 RFLPs, and also allow for differentiation between the *2/*4 and *1/*2*4 genotypes, since if both RFLPs are found, it is possible using the fragment size distribution to tell whether the polymorphisms occur on the same or different alleles.
Allele specific PCR for the exon 7 polymorphism
Genotypes at the *3 site were determined by allele specific PCR, essentially as described by Hayashi et al. (12) . Each DNA sample was amplified in two separate reactions using one of two 5Ј primers: 5Ј-GAAGTGTAT CGGTGAGACCA-3Ј or 5Ј-GAAGTGTATCGGTGAGACCG -3Ј. All reactions included the 3Ј primer: 5Ј-GTAGACAGAGTCTAGGCCTCA-3Ј samples were amplified in a Crocodile II thermocycler (Appligene, Pleasanton, CA) with an initial denaturation at 95°C for 5 min, followed by 30 cycles of 95°C for 1 min, 65°C for 1 min, and 72°C for 1 min, and a final extension at 72°C The category includes: mixed cell carcinoma (n ϭ 6), bronchioalveolar carcinoma (n ϭ 2), and nondifferentiated cancer (n ϭ 4). wt ϭ homozygous wild type; *4 ϭ heterozygous CYP1A1*4 RFLP; *4/*4 ϭ homozygous CYP1A1*4 RFLP. a OR calculated after combining subjects carrying either *4 or *4/*4. b The category includes: mixed cell carcinoma (n ϭ 6), bronchioalveolar carcinoma (n ϭ 2), and nondifferentiated cancer (n ϭ 4). OR are adjusted for sex (male/female) and age (ഛ35, 36-55, Ͼ55 years). Totals may vary due to missing values.
for 10 min. Products were electrophoresed through 1.8% agarose and visualized by ethidium bromide staining.
Statistical analysis
The odds ratio and 95% confidence intervals were computed to assess the relationship between each CYP1A1 polymorphism and lung cancer. This analysis was conducted first for each polymorphism separately, without taking into consideration whether two or more polymorphisms might occur in a single individual, and then for all the possible combinations of the three polymorphisms. Adjustment for possible confounding factors was performed by multiple logistic regression. Student's t-test was used to compare the number of packs of cigarette-years between subjects with and without the *4 RFLP. Data were log transformed to obtain normal distribution. All statistical tests were two-sided (α ϭ 0.05). Heterogeneity between genotype distribution was calculated by χ 2 analysis using the Monte Carlo simulation (22) , which allows comparison of frequencies even when categories contain small numbers or no individuals.
Results
The study population characteristics are illustrated in Table I . Controls were significantly younger than the cases, and smoked significantly less, as expected. Most of the cases were males, while the controls were equally divided between males and females. The adjusted odds ratio of lung cancer with the *4 polymorphism is presented in No association between either the *2 or the *3 polymorphisms and lung cancer was observed in this population (Table  III) .
We stratified the data by the amount of smoking, using the median pack years of smoking observed among controls (15 pack years) as the cutoff. The association between the *4 polymorphism and adenocarcinoma of the lung was present at the lower level of smoking (ഛ15 pack years), but was not seen at the higher level (Table IV) . The mean level of lifetime cigarette consumption was 10.5 Ϯ 13.1 among adenocarcinoma cases carrying the *4 polymorphism, and 38.5 Ϯ 29.5 among the cases negative for the *4 polymorphism (p ϭ 0.005). This pattern was not seen in squamous cell carcinoma cases or in any cases with respect to the other two polymorphisms (Table  IV) . No significant difference in smoking level was observed between controls with respect to the *4 polymorphism (Figure 1 ).
Since each individual may carry different combinations of the three possible polymorphisms, we wanted to classify the subjects with respect to their composite CYP1A1 genotype, taking into account all three polymorphisms simultaneously. The distribution of the complete CYP1A1 genotype in cases and controls, and by main histologic types is reported in Table  V . This analysis did in fact reveal a previously undetected significant association between total lung cancer and the composite genotype *2/*2*3, which corresponds to the simultaneous presence of the homozygous CYP1A1*2 (Msp1) variant and the heterozygous CYP1A1*3 (exon 7) variant, with an OR of 8.4 (1.6-43.2). Both of the two heterozygous *4 genotypes (*1/*4 and *2/*4) were associated with increased risk for adenocarcinoma, but because of the small sample size, neither was significant alone. Analysis of the total genotype distribution revealed a significant heterogeneity between that of the lung cancer cases and controls (χ 2 22.5; p ϭ 0.023). The same result was also seen for the adenocarcinoma genotype distribution compared to controls. (χ 2 25.2; p ϭ 0.016).
Discussion
Our finding of a lack of association between the *4 polymorphism and overall lung cancer risk has also been reported by two other groups (10, 11) . The results reported here on the association of the *4 RFLP with adenocarcinoma of the lung in African Americans are consistent with our previous findings (9) . Another group has found no association (11) . We see no clear reason for the discrepancy between our results and those from London et al. (11) . The sizes of the study populations are roughly equivalent, and the frequency of the *4 polymorphism in controls (which were selected differently in the two studies) is very similar. Adenocarcinoma of the lung is the wt ϭ homozygous wild type; *2 ϭ heterozygous CYP1A1*2 RFLP; *2/*2 ϭ homozygous CYP1A1*2 RFLP; *3 ϭ heterozygous CYP1A1*3 RFLP; *3/*3 ϭ homozygous CYP1A1*3 RFLP; *4 ϭ heterozygous CYP1A1*4 RFLP; *4/*4 ϭ homozygous CYP1A1*4 RFLP. a Median level among the controls. b OR adjusted for sex (male/female) and age (ഛ35, 36-55, Ͼ55 years). Totals may vary due to missing values. most common histologic type in women (23) . In our study, 32% of adenocarcinoma cases were women, compared to 16% of squamous cell carcinoma cases. Although the frequency of the *4 polymorphism was slightly higher in women (16%) than in men (13%), stratification by gender had no effect on the risk of adenocarcinoma associated with the *4 RFLP (OR: 3.2 for women, 2.3 for men, versus 2.8 for all subjects). The reason for a selective association between the *4 polymorphism and adenocarcinoma of the lung is not known. Experimental studies (24) have shown a selective activity of P4501A isoenzymes in the lung tissue where adenocarcinoma develops. Furthermore, since adenocarcinoma is less strongly associated with smoking, it is possible that the relatively weaker effect of a genetic susceptibility factor would be more evident in this histologic type, in analogy with the low dose effect discussed below. Hopefully a larger case control study using cases from various geographical areas of the US, (or perhaps more importantly, from Africa) will be able to resolve the true role of the *4 polymorphism in African-American lung adenocarcinoma. Our lack of detection of any association of the other two polymorphisms (considered separately) with lung cancer risk confirms data published from other laboratories on African Americans and Caucasians (6, 17, 18) . We also report here for the first time an analysis of lung cancer risk in African Americans as a function of the complete composite genotype, taking into account all three polymorphisms in each individual. This approach makes sense if one considers the CYP1A1 gene to consist of at least eight different alleles, none of which can be considered the wild type. In other work we have reported that the frequency of the *1/*1 genotype (absence of any polymorphism) is present in less than half of Asians or Africans, and therefore cannot be considered the human wild type allele (14) . It is possible that each allele may have different functional significance related to the metabolism of carcinogens, and therefore it is conceivable that different cancer risk may be associated with different complex and rare alleles. Our finding of a significant increase in lung cancer risk associated with one of these rare alleles (*2/*2*3), is clearly preliminary, but should be further investigated in African Americans as well as other populations. The biological mechanisms responsible for the effects seen are still unclear. We have previously found a significant increase in AHH enzymatic activity associated with the CYP1A1*3 polymorphism, and with the combined *2/*3 genotype in Asians (25), however we do not yet know the functional significance, if any, of the *4 or the other polymorphisms in African Americans. We have previously suggested, based on population genetic studies (14) , that in African Americans the *2 and possibly the *4 RLFPs may be markers for genetic variants at a different locus, since no linkage between these two polymorphisms and the functional *3 polymorphism is seen in this ethnic group (14) .
Several groups including our own, have reported that the interaction of metabolic gene polymorphisms with exposure to cigarette smoke appears to be more important at low levels of exposure (9, 16, 26, 27) . This type of gene-environment interaction, which has been labeled type 2 interaction by Khouri and James (28) , and Ottman (29), often appears to exhibit this 'inverse dose effect', which should not be confused with a protective effect. In this paper, we observed that the association between the *4 polymorphism and adenocarcinoma 816 of the lung is strong at low dose of cigarette smoking (Ͻ15 pack years), while is almost absent at high doses. This conclusion would be further strengthened if dose were measured in cigarettes/day, rather than in 'pack-years' of smoking. However, in this study, only the latter measurement was available. Our results suggest that polymorphisms in metabolic genes may have a greater role in determining cancer risk at low level of exposure to carcinogens, such as environmental exposure or passive smoking (30) . This aspect is important from a public health point of view, since a large part of the general population is exposed to low levels of environmental carcinogens, and the frequencies of such polymorphisms are relatively high compared to 'single' cancer susceptibility genes.
